earnings
confidence high
sentiment positive
materiality 0.85
Catalyst Pharma Q3 revenue $128.7M (+25% YoY); GAAP EPS $0.35; raises FY guidance
CATALYST PHARMACEUTICALS, INC.
2024-Q3 EPS reported
$0.87
revenue$349,914,000
- Total revenue $128.7M, up 25.3% YoY; GAAP net income $43.9M ($0.35 diluted).
- Non-GAAP net income $71.1M ($0.57 diluted); cash and equivalents $442.3M.
- FIRDAPSE net rev $79.3M (+19.7%); AGAMREE early launch $15.0M; FYCOMPA $32.1M.
- Full-year 2024 total revenue guidance raised to $475-485M.
- Q3 2023 GAAP net loss of $30.8M vs. current net income of $43.9M.